VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer
Үндсэн зохиолчид: | , , , , , , , , , , , , , , |
---|---|
Формат: | Conference item |
Хэвлэсэн: |
American Society of Clinical Oncology
2018
|
Тойм: |
---|